



BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakinagar Road, Andheri (East), Mumbai - 400 072.

AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2014

(₹ in Lacs)

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2014. (₹ in Lacs)

PART-I		STANDALONE						CONSOLIDATED		SYNOPSIS				CONSOLIDATED	
SR. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED	SR. No.	PARTICULARS	SYNOPSIS		CONSOLIDATED		
		31.03.2014 (AUDITED)*	31.12.2013 (UNAUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)			31.03.2014 (AUDITED)	Mar-14	Mar-13	Mar-14	Mar-13
1	Income From Operations								1	Equity and Liabilities					
	(a) Net Sales (Net of Excise Duty)	5,373.14	5,885.77	10,012.71	28,348.95	34,810.82	33,973.26	35,083.24	1	Shareholders' Funds:					
	(b) Other Operating Income	178.84	114.98	250.70	998.43	657.50	712.68	579.30		(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47	
										(ii) Reserves and Surplus	30,482.81	24,842.04	27,856.85	24,768.10	
										(iii) Money received against Share Warrants					
										Sub-total - Shareholders' Funds	31,514.28	25,873.51	28,888.32	25,800.57	
	Total Income from Operations (Net)	5,552.00	6,000.75	10,263.41	29,347.38	35,468.32	34,685.94	35,662.54	2	Minority Interest			1016.26	1,378.87	
2	Expenses								3	Non-Current Liabilities					
	a) Consumption of Raw Materials	2,889.09	2,206.27	5,598.20	13,517.32	18,800.50	15,564.09	20,082.50		(i) Long Term Borrowings	4,513.34	5,387.81	8,756.83	9,129.84	
	b) Purchase of Traded Goods	528.50		52.50	1,030.40	350.28	1,551.55	972.44		(ii) Deferred Tax Liabilities (Net)	618.80	436.58	695.79	487.84	
	c) Increase/Decrease in Stock in Trade	(369.38)	185.13	(91.65)	60.57	(511.72)	(12.87)	(623.17)		(iii) Other Long Term Liabilities					
	d) Employee Benefit Expenses	340.48	323.94	272.80	1,232.81	897.07	2,345.28	1,507.85		(iv) Long Term Provisions	78.23	73.81	78.23	73.81	
	e) Depreciation / Amortisation	71.57	128.04	119.71	448.16	442.78	1,068.18	802.54		Sub-total - Non-Current Liabilities	5,270.37	5,898.20	9,531.85	9,691.58	
	f) Other Expenditure	1,363.04	1,370.55	2,595.71	8,314.48	5,604.21	7,932.83	6,707.28	4	Current Liabilities					
	Total Expenses	4,806.09	4,183.93	8,934.37	22,862.82	25,732.90	28,410.37	28,148.44		(i) Short Term Borrowings	2,314.16	1,820.75	5,704.90	4,515.75	
3	Profit from Operations Before other Income & Finance Cost & Exceptional Items (1-2)	645.91	1,816.82	1,829.04	6,484.56	9,735.42	6,275.57	10,513.10		(ii) Trade Payables	5,698.97	9,242.53	8,235.44	11,815.12	
4	Other Income	90.01	145.48	731.82	2,789.31	1,503.28	2,577.58	1,406.93		(iii) Other Current Liabilities	2,861.23	1,381.71	4,211.63	2,444.69	
5	Profit from ordinary activities before Finance Cost (3+4)	735.92	1,962.30	2,600.86	9,273.87	11,238.70	8,853.15	11,920.08		(iv) Short Term Provisions	879.11	1,422.23	689.38	1,443.50	
6	Finance Cost	308.44	220.86	221.13	843.63	655.46	1,788.23	971.84		Sub-total - Current Liabilities	11,543.47	13,867.22	19,043.35	20,218.06	
7	Profit from ordinary activities after Finance Cost but before Exceptional Items (5-6)	427.48	1,741.44	2,159.73	8,430.24	10,583.24	7,064.92	10,948.24		Total Liabilities	48,837.45	45,615.03	68,278.58	57,091.09	
8	Exceptional Items								II. Assets						
9	Profit from Ordinary Activities Before Tax (7-8)	427.48	1,741.44	2,159.73	8,430.24	10,583.24	7,064.92	10,948.24	1	Non-current Assets					
10	Tax Expense (including Deferred Tax)	272.00	888.58	1,569.28	2,037.13	4,815.93	2,852.67	4,888.78		(a) Fixed Assets	5,783.71	4,944.14	21,754.00	16,887.92	
11	Net Profit for the Period (9-10)	155.48	1,052.86	590.45	6,393.11	5,767.31	4,212.25	5,959.46		(b) Non-current Investments	1,022.53	1,822.02	1.01	1.01	
12	Minority Interest									(c) Deferred Tax Assets					
13	Net Profit After Tax & Minority Interest (11-12)	155.48	1,052.86	590.45	6,393.11	5,767.31	4,212.25	5,959.46		(d) Long Term Loans and Advances	16,817.88	8,517.28	901.57	5,072.32	
14	Paid - Up Equity Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47		(e) Other Non Current Assets	188.66	241.20	188.66	241.20	
15	Reserves Excluding Revaluation Reserve (As Per Balance Sheet)				30,457.84	24,842.03	27,856.85	24,768.10		Sub-total - Non-current Assets	18,812.76	16,824.64	22,866.24	22,902.45	
16	Basic and Diluted EPS (Not Annualised)	0.15	1.03	0.55	6.23	5.50	3.97	5.60	2	Current Assets					
PART-II		STANDALONE						CONSOLIDATED		SYNOPSIS					
SR. No.	PARTICULARS	31.03.2014 (AUDITED)*	31.12.2013 (UNAUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	1	The company operates primarily in the pharmaceutical business and its main products are reported as follows:				
A	Particulars of Shareholding									2	The consolidated results include the Audited Financial Results of parent company, its subsidiaries namely Bliss GVS International Pvt Ltd (100% Holding), Bliss India Life Sciences Pvt Ltd (51% Holding), Bliss GVS Clinic Healthcare Pvt Ltd (100% Holding), Krenom Pharma Pvt Ltd (70% Holding), Bliss Life Pvt Ltd (51%) & its step down subsidiaries.				
1	Aggregate of Non-promoter Shareholding	36156842	36156842	36168842	36156842	36168842	36156842	36168842	36156842	3	Tax Expense for the Quarter and Year Ended March 31st, 2014 includes short provision for earlier years Rs. 170.00 Lacs and Quarter and Year Ended March 31st, 2013 includes short provision of Earlier Years of Rs. 1422.06 Lacs (including Net Reversal).				
	No. of Shares (Face Value Rs.1/- Each)	36.06	36.05	35.08	35.06	36.08	35.05	36.09	36.09	4	The Board has recommended a dividend of 50% i.e. Rs. 0.50 per Equity Share for the year Ended 31st March 2014.				
	Percentage of Shareholding (%)									5	Other Income for Year Ended 31st March 2014 includes Revised Exchange gain of Rs. 2175.05 Lacs (Previous Year Ended Rs. 1108.59 Lacs) and Unrealised Exchange Loss (Net) of Rs. 78.68 Lacs. (Previous Year Ended Rs. 242.39 Lacs).				
2	Promoter and Promoter group Shareholding									6	The Figures for the Quarter Ended March 31st, 2014 and 2013 are the balancing figures between the Audited Figures in respect of the full Financial Year and the year to date published results for the nine months ended December 31st, 2013 and 2012.				
	A) Forfeited / Encumbered									7	Previous Year/Period Figures are Regrouped/Rearranged wherever necessary.				
	No. of Shares (Face Value Rs.1/- Each)									8	The above results were reviewed by the Audit committee & were there after approved by the Board at its Meeting held on May 26th, 2014.				
	Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)									FOR BLISS GVS PHARMA LIMITED					
	Percentage of Shares (As % of the Total Share Capital of The Company)									SD/-					
	B) Non - Encumbered									S. N. KAMATH					
	No. of Shares (Face Value Rs.1/- Each)	68989830	68989830	68989830	68989830	68989830	68989830	68989830	68989830	MANAGING DIRECTOR					
	Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	Place : Mumbai					
	Percentage of Shares (As % of the Total Share Capital of The Company)	64.95	64.95	64.92	64.95	64.82	64.86	64.82	64.82	Date : 28th May 2014					
SR. No.	PARTICULARS	Quarter Ended 31 March 2014													
B	Investor Complaints														
	Pending at the beginning of the quarter														
	Received during the quarter														
	Disposed off during the quarter														
	Remaining unsolved at the end of the quarter														

- The company operates primarily in the pharmaceutical industry as a contract manufacturer.
- The consolidated results include the Audited Financial Results of parent company, its subsidiaries, namely Bliss International Pvt. Ltd. (100% Holding), Bliss India Pvt. Ltd. (100% Holding), Bliss GVS Pvt. Ltd. (51% Holding), Bliss GVS Clinical Healthcare Pvt. Ltd. (100% Holding), Bliss GVS Pharma Pvt. Ltd. (70% Holding), Bliss GVS Pvt. Ltd. (51%) & its step down subsidiaries.
- Tax Expenses for the Quarter and Year Ended March 31st, 2014 includes short provision for earlier years Rs. 170.00 Lacs, and Quarter and Year Ended March 31st, 2013 includes short provision of Earlier Years of Rs. 1422.66 Lacs (including Mat Reversal).
- The Board has recommended a dividend of 50% i.e. Rs. 0.50 per Equity Share for the year ended 31st March 2014.
- Other income for Year Ended 31st March 2014 includes Revised Exchange gain of Rs. 2175.05 Lacs (Previous Year Ended Rs. 1108.59 Lacs) and Unrealized Exchange Loss (Net) of Rs. 78.68 Lacs (Previous Year Ended Rs. 242.80 Lacs).
- The figures for the Quarter Ended March 31st, 2014 and 2013 are the balancing figures between the Audited figures in respect of the full Financial Year and the year to date published results for the nine months ended December 31st, 2013 and 2012.
- Previous Year/Period figures are Regrouped/Rearranged wherever necessary.
- The above results were reviewed by the Audit committee and were there after approved by the Board at the Meeting held on May 26th 2014.

FOR BLISS GVS PHARMA LIMITED
SD/-
S. N. KAMATH
MANAGING DIRECTOR

Place : Mumbai
Date : 26th May 2014

SR. No.	PARTICULARS	Quarter Ended 31 March 2014
B	Investor Complaints	
	Pending at the beginning of the quarter	-
	Received during the quarter	1
	Disposed off during the quarter	1
	Remaining unsolved at the end of the quarter	-